Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improvement of cognitive function in bipolar disorder by aripiprazole adjunct treatment
DRKS00004316Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of aripiprazole in bipolar disorder (BD), sponsored by Bristol Myers Squibb. Primary endpoint: Improvement of cognitive function. Started Sep 2012; status: recruiting.
02
Drugs
aripiprazole
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on DRKS00004316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004316.